awmsg logo



pomalidomide (Imnovid®)


Reference No. 2590

Publication date:
02/09/2015


Appraisal information

pomalidomide (Imnovid®) 1 mg capsule
pomalidomide (Imnovid®) 2 mg capsule
pomalidomide (Imnovid®) 3 mg capsule
pomalidomide (Imnovid®) 4 mg capsule


Company: Celgene Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: 15/04/2015
AWMSG meeting date: 15/07/2015
   
   
Submission Type: Resubmission
Status: Superseded
Advice No: 1315
Ministerial ratification: 27/08/2015

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA427) NICE GUIDANCE ISSUED JANUARY 2017 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Pomalidomide (Imnovid®) is recommended as an option for use within NHS Wales in combination with dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download